Fresenius Sues Actavis Over Generic Diprivan Anesthetic

Actavis Inc. (ACT) was sued by a unit of global health-care products maker Fresenius SE (FRE) over claims the drugmaker infringed four U.S. patents covering the injectable anesthetic Diprivan.

Fresenius Kabi USA, based in Lake Zurich, Illinois, contends Corona, California-based Actavis is planning to market copies of Diprivan in violation of Fresenius’s patent rights, according to a complaint filed today in federal court in Wilmington, Delaware.

“Fresenius will be substantially and irreparably harmed” by the infringement unless it’s stopped by a court,’’ company lawyers said. Fresenius seeks an order prohibiting Actavis and its Watson Laboratories unit from marketing the copies until the patents expire.

Charlie Mayr, an Actavis spokesman, didn’t immediately respond to phone and e-mail messages seeking comment on the lawsuit.

The case is Fresenius Kabi USA LLC v. Watson Laboratories Inc., 13-cv-01015, U.S. District Court, District of Delaware (Wilmington).

To contact the reporter on this story: Phil Milford in Wilmington, Delaware, at pmilford@bloomberg.net.

To contact the editor responsible for this story: Michael Hytha at mhytha@bloomberg.net.

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.